Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticlePractice

Answer: Can you identify this condition?

Jonathan A. Micieli, Michael Surkont and Shawn L. Cohen
Canadian Family Physician January 2010, 56 (1) 36-37;
Jonathan A. Micieli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Surkont
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shawn L. Cohen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Answer to Ophthaproblem continued from page 33

3. Ocular hypertension

Ocular hypertension (OHT) is an asymptomatic condition characterized by an elevated intraocular pressure (IOP) with no detectable visual field or optic disk abnormalities on standard clinical tests. It is estimated that 4% to 7% of those older than 40 years of age in the United States and likely a similar number in Canada have OHT and many are unaware of it.1 The unifying and most important risk factor for developing primary open-angle glaucoma (POAG), a disease of the optic nerve and a leading cause of irreversible blindness worldwide,2 is an elevated IOP; therefore, patients with OHT are considered glaucoma suspects. However, POAG is a heterogeneous disease that requires specific changes in the optic disk and visual field for diagnosis. Not everyone with OHT will develop these features, and many patients diagnosed with POAG will have IOPs in the normal range when first measured, suggesting that various factors contribute to the pathogenesis of this heterogeneous condition.

It is still unknown how elevated pressure in the eye contributes to the development of POAG. Proponents of the mechanical theory suggest that an elevated IOP has a direct effect on the lamina cribrosa and retinal ganglion cell axons, leading to deformation, mechanical stress, and ultimately cell death.3 Independently or together with the elevated IOP, dysfunction of blood flow autoregulation can play a pathogenic role and lead to ischemic hypoxia from the mismatch of perfusion and metabolic demand.4 Interestingly, patients with OHT that progresses to POAG have been reported to have increased arteriolar narrowing compared with those who remain asymptomatic.5

The risk of progression from OHT to POAG can be quantified using a validated risk calculator,6 which considers the patient’s age, mean IOP, central corneal thickness (CCT), vertical cup-to-disk ratio, and visual field defects. As shown in Table 1,6 each parameter is assigned a value, which can then be summed to estimate POAG risk. The prevalence of POAG increases with age and is 4 to 5 times greater among black Americans than among white Americans.7 As increased CCT can overestimate IOP measurements, those with high IOP and decreased CCT are at greater risk than those with the same pressure but greater CCT. Although a corrective formula can adjust for this variable (subtract 4 mm Hg for CCT ≥ 600 μm; add 4 mm Hg for CCT ≤ 500 μm), decreased corneal thickness is also considered an independent risk factor for POAG.8 Moreover, the hollowed-out appearance or “cupping” that is associated with the loss of retinal ganglion cells in glaucoma is incorporated into the risk calculator by the vertical cup-to-disk ratio. Generally, a value greater than 0.5 or considerable asymmetry between the 2 eyes is highly suggestive of glaucomatous atrophy. Finally, peripheral vision is the first to be affected by glaucoma and can be assessed using automated perimetry, although visual field defects cannot usually be detected until about 40% of the retinal ganglion cells are lost.9

View this table:
  • View inline
  • View popup
Table 1.

A calculator to estimate the risk of developing POAG: A) Risk factors and the value of points for each variable; B) Total score of points to estimate the 5-year risk of developing POAG.

Management

This patient’s risk of progression to POAG can be used to guide treatment decisions. Considering this patient’s age of 58 years (2 points), mean IOP of 30 mm Hg (4 points), CCT of 616 μm (no points), vertical cup-to-disk ratio between 0.4 and 0.5 (2 points), and normal visual field (no points), the estimated 5-year risk of progression is about 10% (Table 16). Usually a 5-year risk of 15% or more is cause to initiate IOP-targeted treatment, unless the IOP is unusually high, which would call for immediate attention. Consequently, treatment was not initiated for this patient, but she continues to be monitored closely by her ophthalmologist.

There are 5 main classes of drugs that can be used to diminish IOP: prostaglandin analogues, β-adrenergic antagonists, α2-adrenergic agonists, carbonic anhydrase inhibitors, and cholinergic agonists.10 They act by either reducing the production of aqueous humour by the ciliary body (β-adrenergic antagonists, carbonic anhydrase inhibitors, and α2-adrenergic agonists), increasing uveoscleral outflow of aqueous humour (prostaglandin analogues and α2-adrenergic agonists), or by increasing aqueous outflow through the trabecular meshwork (cholinergic agonists). Although these agents are administered topically, there are still a number of systemic side effects that might manifest in patients using these therapies. The prostaglandin analogues, including latanoprost, are the standard first line of defence for reducing IOP owing to their effectiveness, minimal side effects, and once-daily dosing.11

Recommendations

A regular eye examination is critical for avoiding irreversible vision loss from POAG, as this condition causes no symptoms until the disease is at a late stage. Approximately 50% of cases of POAG go unnoticed and untreated,7 emphasizing the importance of the family physician in identifying at-risk patients (particularly those older than 50 years of age, black patients, and those with a family history of glaucoma) for referral to an ophthalmologist. For those who have OHT and are being followed closely for the development of POAG, annual eye examinations are important to monitor for changes so that treatment can be promptly initiated to prevent irreversible vision loss.

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. 1.↵
    LeibowitzHMKruegerDEMaunderLRMiltonRCKiniMMKahnHAThe Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973–1975Surv Ophthalmol198024Suppl335610
    OpenUrlCrossRefPubMed
  2. 2.↵
    QuigleyHANumber of people with glaucoma worldwideBr J Ophthalmol199680538993
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    BellezzaAJRintalanCJThompsonHWDownsJCHartRTBurgoyneCFDeformation of the lamina cribrosa and anterior scleral canal wall in early experimental glaucomaInvest Ophthalmol Vis Sci200344262337
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    NicolelaMTClinical clues of vascular dysregulation and its association with glaucomaCan J Ophthalmol200843333741
    OpenUrlCrossRefPubMed
  5. 5.↵
    CohenSLLeePPHerndonLWChallaPOverburyOAllinghamRRUsing the arteriolar Pressure Attenuation Index to predict ocular hypertension progression to open-angle glaucomaArch Ophthalmol20031211338
    OpenUrlPubMed
  6. 6.↵
    1. Gordon MO,
    2. Torri V,
    3. Miglior S,
    4. Beiser JA,
    5. Floriani I,
    6. Miller JP,
    7. et al.
    Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertensionOphthalmology20071141109. Epub 2006 Nov 7.
    OpenUrlCrossRefPubMed
  7. 7.↵
    TielschJMSommerAKatzJRoyallRMQuigleyHAJavittJRacial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye SurveyJAMA1991266336974
    OpenUrlCrossRefPubMed
  8. 8.↵
    HerndonLWWeizerJSStinnettSSCentral corneal thickness as a risk factor for advanced glaucoma damageArch Ophthalmol200412211721
    OpenUrlCrossRefPubMed
  9. 9.↵
    HarwerthRSCarter-DawsonLSmithEL3rdBarnesGHoltWFCrawfordMLNeural losses correlated with visual losses in clinical perimetryInvest Ophthalmol Vis Sci2004459315260
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    MarquisREWhitsonJTManagement of glaucoma: focus on pharmacological therapyDrugs Aging2005221121
    OpenUrlCrossRefPubMed
  11. 11.↵
    ParikhRSParikhSRNavinSArunEThomasRPractical approach to medical management of glaucomaIndian J Ophthalmol200856322330
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 56 (1)
Canadian Family Physician
Vol. 56, Issue 1
1 Jan 2010
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Answer: Can you identify this condition?
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Answer: Can you identify this condition?
Jonathan A. Micieli, Michael Surkont, Shawn L. Cohen
Canadian Family Physician Jan 2010, 56 (1) 36-37;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Answer: Can you identify this condition?
Jonathan A. Micieli, Michael Surkont, Shawn L. Cohen
Canadian Family Physician Jan 2010, 56 (1) 36-37;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • 3. Ocular hypertension
    • Management
    • Recommendations
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • Question: Can you identify this condition?
  • Answer: Can you identify this condition?
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Determining if and how older patients can safely stay at home with additional services
  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
Show more Practice

Ophthaproblem

  • Answer: Can you identify this condition?
  • Question: Can you identify this condition?
  • Question: Can you identify this condition?
Show more Ophthaproblem

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire